VALIDATED SIMULTANEOUS HPLC METHOD FOR THE ESTIMATION OF GRAZOPREVIR AND ELBASVIR.

The objective of the research is to create a rapid, uncomplicated, accurate, and cost-effective RPHPLC technique for quantifying the quantities of Grazoprevir and Elbasvir concurrently in both pharmaceutical products and bulk materials. This approach has successfully accomplished the separation of Grazoprevir and Elbasvir in significant quantities. The separation was conducted with a Waters C18 (250 x 4.6 mm x 5 μ particle size) analytical column, with detection at a wavelength of 260 nm. The mobile phase included a blend of Methanol and Phosphate Buffer pH 4.0 at a volumetric ratio of 60:40. The separation was conducted using isocratic elution mode at a flow rate of 1.0 ml/min. Grazoprevir had a retention time of 2.400 minutes, whereas Elbasvir showed a retention length of 3.016 minutes. The quantification of Grazoprevir and Elbasvir was performed by utilizing PDA detection at a wavelength of 260 nm, employing a linear calibration curve. For accurate quantification, the concentration ranges of 20-100 μg/ml (with a correlation value of 0.9999) and 10-50 μg/ml (with a correlation coefficient of 0.999) were used. The suggested approach is well-suited for use in quality-control labs for the quantitative examination of medicines, both when employed separately or in combination, particularly in bulk quantities. This approach is distinguished by its effectiveness, while nevertheless guaranteeing a high degree of accuracy and precision. [ABSTRACT FROM AUTHOR]